BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 30863403)

  • 1. Harnessing CD8
    Warren JA; Clutton G; Goonetilleke N
    Front Immunol; 2019; 10():291. PubMed ID: 30863403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.
    Koofhethile CK; Ndhlovu ZM; Thobakgale-Tshabalala C; Prado JG; Ismail N; Mncube Z; Mkhize L; van der Stok M; Yende N; Walker BD; Goulder PJR; Ndung'u T
    J Virol; 2016 Aug; 90(15):6818-6831. PubMed ID: 27194762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV replication leads to skewed maturation of CD8-positive T-cell responses in infected children.
    Montesano C; Anselmi A; Palma P; Bernardi S; Cicconi R; Mattei M; Castelli-Gattinara G; Ciccozzi M; Colizzi V; Amicosante M
    New Microbiol; 2010 Oct; 33(4):303-9. PubMed ID: 21213588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-Treatment Controllers: Role in HIV "Cure" Research.
    Cockerham LR; Hatano H; Deeks SG
    Curr HIV/AIDS Rep; 2016 Feb; 13(1):1-9. PubMed ID: 26781112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8
    Kwaa AKR; Talana CAG; Blankson JN
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30404799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
    Tebas P; Jadlowsky JK; Shaw PA; Tian L; Esparza E; Brennan AL; Kim S; Naing SY; Richardson MW; Vogel AN; Maldini CR; Kong H; Liu X; Lacey SF; Bauer AM; Mampe F; Richman LP; Lee G; Ando D; Levine BL; Porter DL; Zhao Y; Siegel DL; Bar KJ; June CH; Riley JL
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33571163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two Distinct Mechanisms Leading to Loss of Virological Control in the Rare Group of Antiretroviral Therapy-Naive, Transiently Aviremic Children Living with HIV.
    Vieira VA; Adland E; Grayson NE; Csala A; Richards F; Dacon C; Athavale R; Tsai MH; D'Souza R; Muenchhoff M; Bonsall D; Jooste P; Goulder PJR
    J Virol; 2022 Jan; 96(2):e0153521. PubMed ID: 34757843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection.
    Dyrhol-Riise AM; Voltersvik P; Olofsson J; Asjö B
    AIDS; 1999 Dec; 13(17):2365-76. PubMed ID: 10597778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.
    Omondi FH; Sudderuddin H; Shahid A; Kinloch NN; Jones BR; Miller RL; Tsai O; MacMillan D; Trocha A; Brockman MA; Brumme CJ; Joy JB; Liang R; Walker BD; Brumme ZL
    mBio; 2021 Dec; 12(6):e0249021. PubMed ID: 34781741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.
    Ganesh A; Lemongello D; Lee E; Peterson J; McLaughlin BE; Ferre AL; Gillespie GM; Fuchs D; Deeks SG; Hunt PW; Price RW; Spudich SS; Shacklett BL
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):791-800. PubMed ID: 27019338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-Specific CD8+ T Cell-Mediated Viral Suppression Correlates With the Expression of CD57.
    Jensen SS; Tingstedt JL; Larsen TK; Brandt L; Gerstoft J; Kronborg G; Pedersen C; Fomsgaard A; Karlsson I
    J Acquir Immune Defic Syndr; 2016 Jan; 71(1):8-16. PubMed ID: 26761268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.
    Walker-Sperling VE; Cohen VJ; Tarwater PM; Blankson JN
    J Virol; 2015 Sep; 89(18):9631-8. PubMed ID: 26178987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia.
    Karlsson AC; Younger SR; Martin JN; Grossman Z; Sinclair E; Hunt PW; Hagos E; Nixon DF; Deeks SG
    AIDS; 2004 Apr; 18(7):981-9. PubMed ID: 15096800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysfunctional phenotypes of CD4+ and CD8+ T cells are comparable in patients initiating ART during early or chronic HIV-1 infection.
    Amu S; Lantto Graham R; Bekele Y; Nasi A; Bengtsson C; Rethi B; Sorial S; Meini G; Zazzi M; Hejdeman B; Chiodi F
    Medicine (Baltimore); 2016 Jun; 95(23):e3738. PubMed ID: 27281071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.
    Rosás-Umbert M; Llano A; Bellido R; Olvera A; Ruiz-Riol M; Rocafort M; Fernández MA; Cobarsi P; Crespo M; Dorrell L; Del Romero J; Alcami J; Paredes R; Brander C; Mothe B
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.
    Papasavvas E; Foulkes A; Yin X; Joseph J; Ross B; Azzoni L; Kostman JR; Mounzer K; Shull J; Montaner LJ
    Immunology; 2015 Jul; 145(3):380-90. PubMed ID: 25684333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus.
    Thompson M; Heath SL; Sweeton B; Williams K; Cunningham P; Keele BF; Sen S; Palmer BE; Chomont N; Xu Y; Basu R; Hellerstein MS; Kwa S; Robinson HL
    PLoS One; 2016; 11(10):e0163164. PubMed ID: 27711228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell exhaustion in HIV infection.
    Fenwick C; Joo V; Jacquier P; Noto A; Banga R; Perreau M; Pantaleo G
    Immunol Rev; 2019 Nov; 292(1):149-163. PubMed ID: 31883174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of CD8
    McBrien JB; Kumar NA; Silvestri G
    Eur J Immunol; 2018 Jun; 48(6):898-914. PubMed ID: 29427516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.